Welcome to our dedicated page for Pediatrix Medical Group news (Ticker: MD), a resource for investors and traders seeking the latest updates and insights on Pediatrix Medical Group stock.
Pediatrix Medical Group, Inc. (NYSE: MD) is a physician-led provider of services for women, babies and children, with specialties in obstetrics, maternal-fetal medicine, neonatology and multiple pediatric subspecialties. News about MD stock frequently centers on its financial performance, portfolio management decisions and clinical leadership in neonatal and pediatric care.
Investors following Pediatrix news will see regular quarterly earnings releases that discuss net revenue, net income, Adjusted EBITDA and Adjusted EPS, along with details on same-unit revenue trends, patient volumes, reimbursement-related factors, payor mix and hospital contract administrative fees. These updates often explain how hospital-based and office-based patient services, particularly neonatology services and neonatal intensive care unit (NICU) days, influence the company’s results.
Pediatrix also issues news on strategic and capital allocation actions, such as the authorization of a share repurchase program of up to a specified dollar amount of its outstanding common stock. Such announcements describe the intended use of the program, its term and the flexibility the company retains to adjust or discontinue repurchases. Board and governance developments, including the appointment of independent directors with extensive pediatric health care experience, are disclosed through press releases and related SEC filings.
Beyond financial and governance updates, Pediatrix highlights its role in research, education and quality improvement. News items include information about NEO: The Conference for Neonatology, a long-running educational meeting that addresses advancements and best practices in neonatal care, and about the activities of the Pediatrix Center for Research, Education, Quality and Safety. Readers who monitor MD news can track how these clinical and educational initiatives align with the company’s hospital-based neonatology and pediatric subspecialty services. For ongoing coverage, this page aggregates company press releases and related market-moving updates.
Mednax, Inc. (NYSE: MD) reported a loss from continuing operations of $0.25 per share for Q1 2022, driven by a $57 million pretax loss on debt extinguishment. Net revenue reached $482 million, marking an increase from $446.8 million in Q1 2021. Adjusted EPS improved to $0.33, up from $0.24 in the prior year. The company experienced growth in patient volume, with same-unit revenue rising by 1.3%. However, operational challenges persisted, with a notable decrease in investment income and increased expenses related to practice salaries and benefits.
Mednax, Inc. (NYSE: MD) announced an investor conference call scheduled for April 28, 2022, at 9:00 a.m. ET. The call will discuss operational results for the quarter ending March 31, 2022. A detailed press release will be issued that morning prior to market opening. Mednax is a national medical group providing specialized physician services focused on women, babies, and children through its Pediatrix brand. The company emphasizes coordinated care across various specialties and has a network of over 4,700 clinicians in 38 states and Puerto Rico.
Mednax, Inc. (NYSE: MD) has announced a brand evolution, adopting the Pediatrix® Medical Group brand nationwide. This change reflects their commitment to providing specialized healthcare for women, babies, and children. The company’s unified branding aims to enhance awareness of its extensive services across 40 years of operations.
Pediatrix-affiliated clinicians care for one in four newborns in the U.S., supported by over $25 million in investments for quality improvements. The new logo symbolizes their commitment to coordinated care within obstetrics, maternal-fetal medicine, and pediatric services.
Mednax, Inc. (NYSE: MD) will host two major neonatal medicine conferences in San Diego from March 1-6. The events, Specialty Review in Neonatology and NEO: The Conference for Neonatology, aim to enhance care for premature and critically ill newborns, bringing together around 750 healthcare professionals. Specialty Review focuses on board certification preparation, while NEO provides updates on neonatal management. The conferences feature renowned speakers and offer continuing education credits, emphasizing the commitment to improving clinical outcomes.
Mednax, Inc. (NYSE: MD) will present at J.P. Morgan’s 2022 Global High Yield and Leveraged Finance Conference on February 28, 2022, at 10:00 a.m. ET in Miami. The event will be accessible through live audio webcasts. Mednax is known for providing physician services under the Pediatrix brand, specializing in pediatric and maternal-fetal care with over 4,700 affiliated clinicians across 38 states and Puerto Rico. Founded in 1979, the company emphasizes high-quality, evidence-based care, supported by a strong commitment to research and education.
Mednax, Inc. (NYSE: MD) is set to present at SVB Leerink’s 11th Annual Global Healthcare Conference on February 18, 2022, at 8:40 a.m. ET. This virtual event will feature a live audio webcast for investors. Mednax is a national medical group focused on providing high-quality physician services through its Pediatrix brand, offering care in specialties such as obstetrics and neonatology. The company has over 4,700 affiliated clinicians across 38 states and Puerto Rico, emphasizing coordinated, compassionate medical care.
Mednax, Inc. (NYSE: MD) reported Q4 2021 earnings of $0.47 per share, with an Adjusted EPS of $0.52. The company achieved net revenue of $499 million, up from $416.6 million YoY, while income from continuing operations rose to $68 million. Adjusted EBITDA for the quarter was $81 million, benefiting from $18.4 million in provider relief funds. For 2021, total revenue reached $1.91 billion, with net income of $108 million, or $1.26 per share. Mednax anticipates at least $270 million in Adjusted EBITDA for 2022, excluding further relief fund contributions.
Mednax, Inc. (NYSE: MD) announced the successful issuance of $400 million in unsecured 5.375% Senior Notes due 2030 and a new $450 million Revolving Credit Facility, replacing a $600 million facility. The proceeds were utilized to redeem $1 billion in 6.25% Senior Notes due 2027. Post-transaction, Mednax’s outstanding debt stands at approximately $750 million. The Notes were sold to qualified institutional buyers without registration under the Securities Act.
Mednax, Inc. (NYSE: MD) will hold an investor conference call and webcast on February 17, 2022, at 9:00 a.m. ET, to discuss operational results for the year ended December 31, 2021. A detailed press release will precede the call on the same date. Mednax, a national medical group, specializes in physician services primarily in pediatrics, obstetrics, and neonatology, operating across 38 states and Puerto Rico with over 4,700 clinicians. For more information, visit mednax.com/investors.
Mednax, Inc. (NYSE: MD) has acquired Night Lite Pediatrics, LLC, a pediatric urgent care practice with 13 clinics in Florida. Founded in 2005, Night Lite employs 30 physicians and offers urgent care, telemedicine, and COVID-19 services. This cash transaction is expected to be immediately accretive to earnings, enhancing Mednax's strategy to develop innovative pediatric services powered by Brave Care technology. The clinics will be rebranded to Pediatrix, further expanding Mednax's presence in pediatric care in Florida.